A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal cell carcinoma.

Trial Profile

A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal cell carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Capecitabine
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Dec 2011 Planned end date changed from 1 Jan 2009 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 21 Dec 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 26 Oct 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top